Radeski Skin Clinic
Back to articles
Verified Clinical Post

Immunobiological Therapy: Psoriasis and Stelara

Radeski Skin Clinic2026-09-220 views1 min
Immunobiological Therapy: Psoriasis and Stelara
Immunobiological therapyPsoriasisStelaraUstekinumabDermatologyRadeski Skin Clinic1 min reading time

Immunobiological therapy: psoriasis, Stelara (ustekinumab), personalized approach and safety — Radeski Skin Clinic.

Key takeaways

  • Biologics are selected individually for severe psoriasis
  • Stelara (ustekinumab) has 10+ years of clinical use
  • Methotrexate is limited in reproductive-age women
  • PSOLAR: 87% continued therapy at 4 years
  • Also used in atopic dermatitis, urticaria, and other immune conditions

What is immunobiological therapy?

Despite many systemic options for psoriasis, 40–50% of patients stop treatment due to insufficient effect, intolerance, or adverse reactions.

Patients with moderate to severe psoriasis, comorbidities, and significant allergy history need personalized systemic therapy.

Why modern biologics?

Methotrexate and similar agents with cytostatic and teratogenic effects should be limited in women of reproductive age planning pregnancy. Genetically engineered biologics with a safer profile are preferred.

Stelara (ustekinumab)

The gold standard of biologic therapy is Stelara, used in dermatology for more than 10 years.

Ustekinumab binds the p40 subunit of inflammatory interleukins IL-12 and IL-23, blocking receptor interaction.

Clinical outcomes

  • Joint tropism — effective in psoriatic arthritis.
  • After the fourth injection, nail dystrophy signs may improve.
  • PSOLAR registry: ~87% of 12,000+ patients continued ustekinumab at 4 years.

Stelara maintains strong long-term effectiveness in real-world practice.

At Radeski Clinic

Leading dermatologists at Radeski Skin & Aesthetic Clinic have extensive experience prescribing immunobiological therapy for psoriasis, atopic dermatitis, urticaria, hidradenitis suppurativa, and Darier disease.

Related services: Immunobiological therapy, Psoriasis school, Prices.

When to see a doctor

  • Moderate or severe psoriasis
  • Topical therapy is insufficient
  • Joint pain or nail changes are present
  • Previous systemic drugs were ineffective

Frequently asked questions

Moderate to severe psoriasis, psoriatic arthritis, and other immune-mediated conditions under physician supervision.

Hashtags

#Immunobiologicaltherapy#Psoriasis#Stelara#Ustekinumab#Dermatology#RadeskiSkinClinic

Important note: This article is for general information only and does not replace a medical consultation.

Share this clinical advisory:

Related clinic services